SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Name of each exchange
Title of each class
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 5, 2023, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) increased the size of the Board from nine to ten directors and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately. The Board also appointed Mr. Anastasiou to serve as a member of the Compensation Committee of the Board.
Mr. Anastasiou, age 53, has served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next-generation integrated gene therapy company, since January 2022. Prior to Capsida, from November 2009 to December 2021, Mr. Anastasiou served in various roles at Lundbeck, a pharmaceutical company publicly traded on the Copenhagen Stock Exchange, including most recently as Executive Vice President and President of North America, and prior to that as Chief Commercial Officer for the U.S. and Vice President and General Manager for Psychiatry. In addition, he served as a member of the board of directors of Lundbeck from January 2016 to December 2021. Mr. Anastasiou currently serves on the Global Advisory Board of the Healthcare Businesswomen’s Association and has previously served on the boards of several private organizations, including the Pharmaceutical Research and Manufacturers Association (PhRMA), Kids Above All and Bear Necessities Pediatric Cancer Foundation. Mr. Anastasiou received a B.A. in Economics and Management from Albion College and an M.B.A. from Kelley School of Business, Indiana University. We believe that Mr. Anastasiou is qualified to serve on our Board because of his extensive experience in the life sciences industry developing and leading multifaceted biotechnology organizations, as well as his demonstrated business acumen.
In connection with his appointment to the Board, Mr. Anastasiou is eligible to receive compensation in accordance with the Company’s Non-Employee Director Compensation Program, as such program may be amended from time to time.
Mr. Anastasiou has entered into the Company’s standard form of indemnification agreement for its directors and officers.
There is no arrangement or understanding pursuant to which Mr. Anastasiou was appointed to the Board. The Board has determined that Mr. Anastasiou is independent under applicable standards. There are no family relationships between Mr. Anastasiou and any director or executive officer of the Company as defined in Item 401(d) of Regulation S-K, and Mr. Anastasiou has no direct or indirect material interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On November 8, 2023, the Company issued a press release announcing the appointment of Mr. Anastasiou to the Board, which is attached to this Current Report on Form 8-K (this “Report”) as Exhibit 99.1 and incorporated herein by reference.
The information in Item 7.01 of this Report (including Exhibit 99.1 attached hereto), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HARMONY BIOSCIENCES HOLDINGS, INC.
Date: November 8, 2023
/s/ Jeffrey M. Dayo, M.D.
Jeffrey M. Dayno, M.D.
President and Chief Executive Officer
HARMONY BIOSCIENCES APPOINTS
PETER Anastasiou To Its Board of Directors
PLYMOUTH MEETING, PA, November 8, 2023 — Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
Peter is Chief Executive Officer of a development stage company Capsida. Anastasiou held various leadership positions at Lundbeck, where he was critical in shaping overall corporate strategy, R&D priorities, and business development. He served as President of North America, overseeing the U.S. and Canadian business operations, and was U.S. Chief Commercial Officer, directing the commercial operations of the company’s neurology and psychiatry franchises and launching new products and indications.
"I am energized to join Harmony’s Board of Directors at this critical stage of growth for the company. The mission of bringing new treatment options to people living with profound unmet medical needs is a great passion to which I have dedicated my entire professional career," said Anastasiou. "I look forward to supporting this dedicated management team and working with the other visionary leaders on the board of directors as we explore opportunities to bring new treatments to people living with rare neurological diseases."
“Peter’s CNS and business development expertise will support Harmony’s growth priorities,” said Harmony Biosciences Chairman Jeff Aronin. “He brings good experience developing and commercializing new therapeutics for patients with unmet medical needs. Peter aligns with our mission and priorities.”
Before Lundbeck, Anastasiou held management roles at Neuronetics, Inc., Bristol-Myers Squibb Company, and Eli Lilly. He is actively involved in the Healthcare Businesswomen’s Association's (HBA) global advisory board, which awarded him the 2019 HBA Honorable Mentor for his work advocating for gender parity in life science leadership.
Anastasiou holds an MBA from the Kelley School of Business at Indiana University and a BA in economics and management from Albion College.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life
can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Harmony Biosciences Investor Contact:
Luis Sanay, CFA